Page 14 - Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

CUAJ – Consensus Statement Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

metastatic urothelial carcinoma: Vinflunine and beyond - a comprehensive review of the
current literature. J Urol 2016;195:254-63.
30. Han KS, Joung JY, Kim TS, et al. Methotrexate, vinblastine, doxorubicin and cisplatin
combination regimen as salvage chemotherapy for patients with advanced or metastatic
transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J
Cancer 2008;98:86-90.
31. Kattan J, Culine S, Theodore C, et al. Letters to the editor: Second-line M-VAC therapy in
patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann
Oncol 1993;4:793-94.
32. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive
care compared with best supportive care alone after a platinum-containing regimen in
patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol
2009;27:4454-61.
33. Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet
chemotherapy as salvage therapy for metastatic urothelial cancer: A systematic review and
meta-analysis. Ann Oncol 2016;27:49-61.
34. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients
with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-40.
35. Papamichael D, Gallagher CJ, Oliver RTD, et al. Phase II study of paclitaxel in pretreated
patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer
1997;75:606-07.
36. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with
advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-57.
37. Ko Y, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-
line treatment of metastatic urothelial carcinoma : a single group , multicentre , phase 2
study. Lancet Oncol 2013;14:769-76.
38. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for
advanced urothelial carcinoma. N Engl J Med 2017;376:1015-26.
39. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in
patients with platinum-treated locally advanced or metastatic urothelial carcinoma
(IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet
2017;391:748-57.
40. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic
urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm,
phase 1/2 trial. Lancet Oncol 2016;17:1590-98.
41. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma
after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet
Oncol 2017;18:312-22.
42. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736),
an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with
advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119-125.
43. Powles T, O'Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally
advanced or metastatic urothelial carcinoma: Updated results From a phase 1/2 open-label
Study. JAMA Oncol 2017;3:e172411.